Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Use of autologous stem cell transplant in multiple myeloma

18th Congress of EHA

13 - 14 Jun 2013

Published: 19 Jun 2013

Views: 6602

Rating:

Save

Dr Elena Zamagni - Bologna University School of Medicine, Bologna, Italy

Dr Elena Zamagni talks to ecancer about autologous stem cell transplant at the 18th EHA Congress in Stockholm, Sweden.

Dr Zamagni highlights the relationship between increasing chemotherapy after transplantation and increasing progression free and overall survival from two clinical trials.

Related Videos

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India

Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

Ponatinib is better than imatinib for frontline treatment of newly diagnosed...

Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia ( Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible...

Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis ( Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain )

Treatment of multiple myeloma in Turkey

Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey

Treatment of multiple myeloma in Turkey ( Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey )

The evolving paradigm in management of Multiple Myeloma

D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

The evolving paradigm in management of Multiple Myeloma ( D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )

Multiple myeloma (A cancer arising from plasma cells)

Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal

Multiple myeloma (A cancer arising from plasma cells) ( Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal )

More from ecancer